cbs-psp-plasma-biomarkers

Plasma Biomarkers for Corticobasal Syndrome and Progressive Supranuclear Palsy

Overview

Plasma biomarkers offer a minimally invasive, accessible alternative to CSF biomarkers for the antemortem diagnosis and pathological classification of corticobasal syndrome (CBS). Recent advances in ultrasensitive assay technologies have enabled reliable detection of neurodegeneration-related proteins in blood, making plasma biomarkers increasingly important for clinical practice and research. [@plasma2024]

Key Plasma Biomarker Categories

Tau Protein Biomarkers

Plasma Biomarkers for Corticobasal Syndrome and Progressive Supranuclear Palsy

Overview

Plasma biomarkers offer a minimally invasive, accessible alternative to CSF biomarkers for the antemortem diagnosis and pathological classification of corticobasal syndrome (CBS). Recent advances in ultrasensitive assay technologies have enabled reliable detection of neurodegeneration-related proteins in blood, making plasma biomarkers increasingly important for clinical practice and research. [@plasma2024]

Key Plasma Biomarker Categories

Tau Protein Biomarkers

Phosphorylated Tau (p-tau)

p-tau217 [@plasma2024a]

• Shows exceptional sensitivity for detecting AD pathology
• Can distinguish CBS-AD from CBS due to primary tauopathies
• Higher diagnostic accuracy than p-tau181 in head-to-head comparisons
• Correlates with cortical tau burden on PET

• Most extensively validated plasma biomarker
• Elevated in CBS patients with AD co-pathology
• Can differentiate PSP from CBS in some studies, though with limited specificity

• May be more specific for AD pathology in early disease stages
• Lower levels in PSP compared to CBS-AD

• Emerging marker with potential for tauopathy differentiation

Total Tau

• Less specific than p-tau variants
• Elevated in advanced disease stages
• Correlates with overall neurodegeneration severity

β-Amyloid Biomarkers

Aβ42/Aβ40 Ratio

• Plasma ratio mirrors CSF findings with good accuracy
• Reduced ratio predicts AD pathology in CBS patients
• Important for treatment stratification (anti-amyloid therapy eligibility)
• Requires careful preanalytical handling

Aβ40 and Aβ42 Absolute Levels

• Both typically reduced in presence of amyloid pathology
• Ratio more reliable than absolute levels

Neurodegeneration Markers

Neurofilament Light Chain (NfL)

• Highly sensitive marker for axonal damage
• Elevated in both CBS and PSP compared to controls
• Correlates with disease severity and progression rate
• Useful for monitoring disease progression in clinical trials
• Not specific to underlying pathology

Neurofilament Heavy Chain (pNfH)

• More specific for cortical neurodegeneration
• Correlates with cortical atrophy measures
• Higher levels associated with more rapid progression

Glial Fibrillary Acidic Protein (GFAP)

• Marker of astrocyte activation
• Elevated in neurodegenerative conditions
• May help differentiate CBS from other parkinsonian disorders

α-Synuclein Biomarkers

Seed Amplification Assays (SAA)

• RT-QuIC and PMCA can detect pathological α-synuclein in plasma
• Positive in CBS cases with Lewy body pathology
• Specificity challenges remain

Plasma Total α-Synuclein

• Generally lower in CBS with Lewy body pathology
• Less reliable than CSF measurements

Clinical Applications

Differential Diagnosis

Plasma biomarkers assist in distinguishing:

• CBS from PSP (overlapping clinical features)
• CBS-AD from CBS due to primary tauopathies
• CBS with Lewy body pathology from other subtypes

Disease Monitoring

• NfL trajectories can predict progression
• Biomarker changes over time may reflect treatment response
• Useful for clinical trial endpoint selection

Treatment Stratification

• Aβ42/Aβ40 ratio guides anti-amyloid therapy decisions
• Biomarker profiles help select patients for targeted trials
• Enables pathology-driven clinical trial enrichment

Emerging Research

Multimodal Biomarker Panels

Recent studies suggest that combining multiple plasma biomarkers improves diagnostic accuracy:

• p-tau217 + NfL + Aβ42/Aβ40
• p-tau181 + GFAP + NfL
• Machine learning models integrating multiple markers

Comparison of Plasma vs CSF

Studies show good correlation between plasma and CSF biomarkers for:

• p-tau181 (moderate correlation)
• NfL (strong correlation)
• Aβ42/Aβ40 (moderate correlation)

• Patient accessibility
• Repeated sampling
• Cost-effectiveness

Prognostic Value

NfL as a Prognostic Marker

Neurofilament light chain (NfL) has emerged as a robust prognostic biomarker in atypical parkinsonian disorders:

• Baseline NfL levels predict disease progression rate in both CBS and PSP [@plasma2025]
• Longitudinal NfL trajectories correlate with clinical deterioration measured by standard rating scales (MDS-UPDRS, PSP rating scale)
• Rapid progressors (defined by >10 points/year decline on MDS-UPDRS) show significantly higher baseline NfL compared to slow progressors
• NfL doubling time of <6 months is associated with more aggressive disease phenotype

p-tau217 Prognostic Utility

• Elevated p-tau217 in CBS patients predicts faster cognitive decline
• Correlates with cortical tau burden on PET, which is associated with more severe dementia
• May identify patients who would benefit from early anti-amyloid therapeutic intervention

p-tau181 Prognostic Value

• Higher baseline p-tau181 levels associated with more rapid motor progression in PSP
• Levels correlate with brain atrophy rates on serial MRI

GFAP as a Prognostic Marker

• Elevated GFAP predicts faster disease progression in some studies
• May reflect astrocyte-mediated neuroinflammatory component driving disease severity

Correlation with Disease Progression

Biomarker Trajectories Over Time

| Biomarker | Disease Stage | Expected Change | Clinical Correlation |
|-----------|--------------|-----------------|----------------------|
| NfL | Early → Advanced | 2-3x increase | Motor and cognitive decline |
| p-tau217 | Early → Advanced | Progressive increase | Cortical tau spread |
| p-tau181 | Early → Advanced | Moderate increase | Disease severity |
| GFAP | Early → Advanced | Gradual increase | Neuroinflammation burden |

Imaging-Biomarker Correlations

• NfL correlates with rates of cortical atrophy and white matter damage on MRI
• p-tau217 correlates with cortical tau PET standardized uptake value ratios (SUVRs)
• p-tau181 correlates with both cortical and subcortical tau deposition
• GFAP correlates with regional brain hypometabolism on FDG-PET

Clinical-Biomarker Correlations

• Higher baseline NfL predicts earlier loss of ambulation in PSP
• Elevated p-tau217/p-tau181 correlates with earlier onset of cognitive impairment
• Combined biomarker profiles can stratify patients into distinct progression phenotypes

Plasma vs CSF Biomarker Comparison

Biomarker Correlation Coefficients

| Biomarker | Plasma-CSF Correlation | Clinical Implication |
|-----------|------------------------|---------------------|
| NfL | r = 0.75-0.85 | Strong — plasma NfL reliably reflects CSF levels |
| p-tau181 | r = 0.50-0.65 | Moderate — both useful but not interchangeable |
| p-tau217 | r = 0.55-0.70 | Moderate — good for screening but CSF more precise |
| Aβ42/Aβ40 | r = 0.45-0.60 | Moderate — ratio more consistent than absolute values |
| GFAP | r = 0.40-0.55 | Moderate — plasma GFAP captures different pool |

Advantages of Plasma Testing

Advantages of CSF Testing

Clinical Implementation Recommendations

• Initial diagnostic workup: Plasma biomarkers for broad screening
• Confirmatory testing: CSF collection when plasma results are equivocal
• Disease monitoring: Plasma NfL for longitudinal tracking
• Clinical trials: Plasma for enrollment; CSF for mechanistic biomarkers

Clinical Implementation Guidelines

p-tau217 Cutoff Values for Differential Diagnosis

The following cutoff values are derived from published studies using the Fujirebio Lumipulse and Simoa platforms. Different assays have platform-specific thresholds; these values should be interpreted using the reference ranges provided by the testing laboratory.

| Condition | p-tau217 (Lumipulse) | p-tau217 (Simoa) | Interpretation |
|-----------|---------------------|---------------------|-----------------|
| Control | < 0.4 pg/mL | < 8.0 pg/mL | Normal range |
| AD | > 0.8 pg/mL | > 15.0 pg/mL | Elevated — supports AD biology |
| PSP | 0.4-0.7 pg/mL | 8.0-12.0 pg/mL | Borderline — may indicate pure 4R tauopathy |
| CBS (non-AD) | 0.4-0.7 pg/mL | 8.0-12.0 pg/mL | Borderline — pure CBS without co-pathology |
| CBS-AD | > 0.8 pg/mL | > 15.0 pg/mL | Elevated — suggests AD co-pathology |

Key clinical interpretation points:

• AD vs. PSP differential: p-tau217 values > 0.8 pg/mL (Lumipulse) strongly favor AD co-pathology over pure PSP. Values in the 0.4-0.7 pg/mL range are typical for PSP and do not reliably exclude PSP when clinical features are present.
• CBS subtyping: Elevated p-tau217 (> 0.8 pg/mL) in a CBS patient suggests underlying AD co-pathology, which may influence treatment decisions (e.g., anti-amyloid therapy eligibility) and prognostic counseling.
• Gray zone: Values between 0.6-0.8 pg/mL require clinical correlation with imaging and neuropsychological testing.

Reference Laboratory Comparison

Mayo Clinic Laboratories

• Uses Simoa platform for plasma p-tau217
• Reference range: < 8.0 pg/mL (cognitively normal controls)
• Provides age-adjusted reference ranges for patients > 65 years

• Uses multiple platforms in biomarker harmonization studies
• Published cross-platform conversion factors available
• Reference: [NACC Biomarker Laboratory](https://www.alz.org/)

Clinical Implementation Workflow

• NfL > 20 pg/mL: Suggests active neurodegeneration regardless of etiology
• p-tau217 > 0.8 pg/mL: Supports AD-type biology
• Both elevated: High likelihood of AD co-pathology
• NfL elevated + p-tau217 normal: Consider pure 4R tauopathy (PSP, CBD)

Insurance Coverage

Medicare: p-tau217 testing is covered under LCD (Local Coverage Determination) for:

• Progressive supranuclear palsy (PSP) diagnostic workup
• Corticobasal syndrome (CBS) differential diagnosis
• Cognitive impairment with atypical features

• Clinical uncertainty exists after standard evaluation
• Patient is a candidate for disease-modifying therapy
• Documentation supports medical necessity

Challenges and Limitations

See Also

• [CBS/PSP CSF Biomarkers](/biomarkers/cbs-psp-csf-biomarkers) — Cerebrospinal fluid biomarker profiles
• [CBS/PSP Imaging Biomarkers](/biomarkers/cbs-psp-imaging-biomarkers) — Neuroimaging biomarker approaches
• [Alzheimer's Disease](/diseases/alzheimers-disease) — AD biomarker framework
• [Parkinson's Disease](/diseases/parkinsons-disease) — α-synuclein biomarkers

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

References